Become A Featured Company

Empower Clinics Positioned As Cannabis Disrupts Pharmaceutical Industry

Ryan Allway

July 23rd, 2018

Exclusive, News, Top Story

Recreational cannabis may be capturing headlines throughout North America, but medical cannabis remains the most established form of cannabis legalization in the United States. Thirty states have already legalized medical cannabis, while a bipartisan group of legislators introduced a bill earlier this year that could protect state marijuana legalization, medical marijuana, and decriminalization laws from federal interference.

With US medical marijuana retail expenditures estimated around $3 billion for 2017, it’s already an attractive market. A study in 2016 found that, in states with medical cannabis laws, Medicare prescriptions fell on average 11% for conditions commonly treated with cannabis. That 11% is no small slice of the prescription drug pie. Take just the most prevalent indication for medical marijuana users, chronic pain management, and the growth potential is astounding. According to Transparency Market Research, the global market for pain management is expected to grow from about $62 billion in 2016 to about $88 billion in 2025.

That’s a lot of opportunity, even when using the 11% figure for the market potential of cannabis as an alternative to prescription pharmaceuticals, the potential impact impact is billions of dollars.

Medical Marijuana Patient Breakdown

Empower Clinics Inc. (CSE: EPW) is capitalizing on these trends by establishing a nationwide network of medical cannabis clinics aimed at helping patients navigate a confusing market for cannabinoid-based treatments for various medical conditions. Empower is the first publicly traded medical marijuana clinic company with operations in the United States.

The Need for Medical Cannabis Clinics

The medical cannabis industry is changing quickly. Scientific research, hampered by federal regulations for years but on the rise recently, has shown important medical benefits from cannabis. Patients with real medical needs are increasingly looking at cannabis as an alternative to conventional treatments. It used to be that getting a ‘green card’ for medical purposes was mostly used as an avenue for legalized possession. Now, non-cannabis users are increasingly pursuing cannabis treatments, and they are looking for trustworthy medical advice and non-synthetic drug alternatives.

Cannabis retail shops are not medical clinics and do not have the expertise to diagnose conditions and prescribe treatments. The medical marijuana retail model started with people filling prescriptions from doctors but has become entangled in recreational sales. In short, budtenders are not doctors. There is a real need for licensed physicians, trained in the effects specific cannabinoids can have on specific conditions, to provide professional medical advice and patient care, and this is the Empower Clinic opportunity.

Even when licensed physicians are involved, most clinics do not have their own in-house formulated products so they are subject to the whims of what is available in local cannabis retailers. The store may not offer the ideal cannabinoid-based product for the treatment of a patient’s medical condition. Additionally, the prescribing physician cannot control the quality or reliability of the products offered at the retail store.

Building a Leading Presence

Empower Clinics is solving these issues by spreading its proven clinic business model and proprietary cannabis formulas across the US in legal medical jurisdictions. The company currently has 15 clinics across three states (Oregon, Washington, and Illinois) that are staffed with physicians from leading hospitals and medical schools, including Harvard, Johns Hopkins, and UCLA. In Oregon, Empower is responsible for issuing more than ⅓ of the state’s medical cards. Since its inception, the company has helped over 90,000 patients and has a roster of more than 27,000 active patients. Revenue from these patients topped $1.6 million last year and those figures are only projected to grow over the coming years.

After raising C$4 million in a private placement, the company looks to begin the process of building out a national clinic brand across all 30 states that have legalized medical cannabis with high-quality physicians, innovative patient tools (such as its mobile app), and a line of branded medical products. The company has already developed seven unique products under the Sollievo brand name that are available in more than 150 dispensaries in Portland alone.

Executive Team Experience

CEO Craig Snyder, a former US Naval Officer and graduate of the United States Naval Academy, previously founded two companies, SnapNames and Moniker, that he grew and sold. He also held executive positions with two companies from startup through IPO, Marchex and Go2Net. Experienced Board of Directors member Lorne Gertner is a legend in the cannabis industry, co-founder of Tokyo Smoke (now Hiku Brands), Cannasat Pharmaceuticals (first TSX listed medical marijuana company), and PharmaCan Capital (now NASDAQ-listed Cronos Group).

With Mr. Snyder’s start up experience in building young companies and Mr. Gertner’s acclaimed cannabis industry expertise, Empower’s leadership is well versed in creating value for shareholders.

Looking Ahead

Empower Clinics Inc. (CSE: EPW) represents a unique opportunity to capitalize on the medical cannabis industry. With 15 clinics in operation and the right model at the right time, the company is in position to grow across the United States’ legal markets. Investors may want to take note of the stock given the significant growth opportunities ahead.

For more information, visit the company’s website at www.empowerclinics.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading